原文和大致译文:
*************************************************************************************
Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.
Geier MR, Geier DA.
The Genetic Centers of America, Silver Spring, Maryland 20905.
We were initially highly skeptical that differences in the concentrations of thimerosal in vaccines
would have any effect on the incidence rate of neurodevelopmental disorders after childhood
immunization. This study presents the first epidemiologic evidence, based upon tens of millions of
doses of vaccine administered in the United States, that associates increasing thimerosal from
vaccines with neurodevelopmental disorders. Specifically, an analysis of the Vaccine Adverse Events
Reporting System (VAERS) database showed statistical increases in the incidence rate of autism
(relative risk [RR] = 6.0), mental retardation (RR = 6.1), and speech disorders (RR = 2.2) after
thimerosal-containing diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in comparison with
thimerosal-free DTaP vaccines. The male/female ratio indicated that autism (17) and speech disorders
(2.3) were reported more in males than females after thimerosal-containing DTaP vaccines, whereas
mental retardation (1.2) was more evenly reported among male and female vaccine recipients.
Controls were employed to determine if biases were present in the data, but none were found. It was
determined that overall adverse reactions were reported in similar-aged populations after
thimerosal-containing DTaP (2.4 +/- 3.2 years old) and thimerosal-free DTaP (2.1 +/- 2.8 years old)
vaccinations. Acute control adverse reactions such as deaths (RR = 1.0), vasculitis (RR = 1.2),
seizures (RR = 1.6), ED visits (RR = 1.4), total adverse reactions (RR = 1.4), and gastroenteritis (RR
= 1.1) were reported similarly after thimerosal-containing and thimerosal-free DTaP vaccines. An
association between neurodevelopmental disorders and thimerosal-containing DTaP vaccines was
found, but additional studies should be conducted to confirm and extend this study.
PMID: 12773696 [PubMed - in process]
*****************************************************************************************
大致翻译:
研究人员起初也相当怀疑含汞疫苗与神经发育异常发生率有关的可能性.
此流行病研究覆盖全美几千万次儿童疫苗注射数据, 提供世界上首次发表的流行病学证据, 证实儿童疫苗中硫柳汞的
含量增加与神经发育异常有关联.
此研究分析了疫苗副作用报告系统(VAERS)的数据库,在比较了去汞和含汞疫苗DTaP的报告数据,
发现注射含汞疫苗DTaP组中,孤独症(AUTISM), 智力缺陷,语言异常的发病率显著增加 (孤独症的relative risk [RR] = 6.0,
智力缺陷的RR = 6.1,语言异常的RR = 2.2). 其中孤独症的男/女发病率比例为17, 语言异常为2.3,而智力缺陷的性比较均衡
为1.2. 使用了控制组来确定数据中是否有偏差,结果未发现偏差.比较两组报告的其他副作用,对类似年龄组无显著差别.
结论: 含硫柳汞的DTaP疫苗与神经发育异常(neurodevelopmental disorders)有关联. 有必要做更多的研究以进一步确认和扩展
此研究结果.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
注意, 上述研究仅分析了一种含汞疫苗.
请教: 有谁知道 "relative risk [RR]"的确切定义?
<font size="1" color="darkblue">Edited by - 宁刚 重新编辑於 2003/06/05 09:24:43</font> |